Direkt zum Inhalt
Merck

Myotubularin-related protein 14 suppresses cardiac hypertrophy by inhibiting Akt.

Cell death & disease (2020-02-23)
Jie-Lei Zhang, Dian-Hong Zhang, Ya-Peng Li, Lei-Ming Wu, Cui Liang, Rui Yao, Zheng Wang, Sheng-Dong Feng, Zhong-Min Wang, Yan-Zhou Zhang
ZUSAMMENFASSUNG

Cardiac hypertrophy (CH) is an independent risk factor for many cardiovascular diseases, and is one of the primary causes of morbidity and mortality in elderly people. Pathological CH involves excessive protein synthesis, increased cardiomyocyte size, and ultimately the development of heart failure. Myotubularin-related protein 14 (MTMR14) is a member of the myotubularin (MTM)-related protein family, which is involved in apoptosis, aging, inflammation, and autophagy. However, its exact function in CH is still unclear. Herein, we investigated the roles of MTMR14 in CH. We show that MTMR14 expression was increased in hypertrophic mouse hearts. Mice deficient in heart MTMR14 exhibited an aggravated aortic-banding (AB)-induced CH phenotype. In contrast, MTMR14 overexpression prevented pressure overload-induced hypertrophy. At the molecular level, prevention of CH in the absence of MTMR14 involved elevations in Akt pathway components, which are key elements that regulate apoptosis and cell proliferation. These results demonstrate that MTMR14 is a new molecular target for the treatment of CH.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Tamoxifen, ≥99%
Sigma-Aldrich
Anti-α-Actinin Antibody, clone AT6/172, clone AT6/172, Upstate®, from mouse
Sigma-Aldrich
MISSION® esiRNA, targeting human MTMR14